Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Half Year Report 2023

September 27, 2023

OBSV_June 30_Interim financialsDownload

Investor presentations

Wedbush Presentation August 2019 in NYC

ObsEva_Wedbush-August2019_FinalDownload

KOL Event in NYC July 2019

KOL Event July 2019-FINAL_Jul18Download

Jefferies Healthcare Conference Presentation – June 2019

ObsEva_June2019.pdfDownload

ObsEva Short Report 2018

ObsEva_Short_Report_Final_2019_03_06 (2)Download
1 2 3

Press Releases

ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference

press release

April 5, 2016

Geneva, Switzerland, 05 April, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…

Read more

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

press release

March 24, 2016

Geneva, Switzerland, 24 March 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced…

Read more

ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

press release

November 23, 2015

Geneva, Switzerland, 23 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising…

Read more
1 … 79 80 81 82 83 … 85

General Meetings

ObsEva Annual General Meeting 2023

June 29, 2023

Read more

ObsEva Annual General Meeting 2022

May 18, 2022

Read more
1 2 3 4

Upcoming Events

Sorry, there are no events available yes.

 

Stock Information

Latest Press Release

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a…

Read more

Investor Contact


IR@obseva.ch

Media Contact

Media

contact@obseva.ch

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

contact@obseva.ch

Investor relations


IR@obseva.ch

CEO Office

+41 (0)22 552 1550


contact@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue